Cindy Eckert is a passionate advocate for women’s sexual health, with a focus on addressing low sex drive. As the founder and CEO of Sprout Pharmaceuticals, she successfully launched the first FDA-approved pill for female hypoactive sexual desire disorder (HSDD). Despite challenges in gaining approval, Eckert persevered and eventually regained control of the company to ensure the drug, Addyi, reached those in need. In addition to her work with Sprout Pharmaceuticals, Eckert is involved in The Pink Ceiling, an organization that supports innovations in women’s healthcare. One of their projects includes the development of the world’s first flushable pregnancy test.
In an interview, Eckert discussed the disparity in approval timelines between drugs for male and female sexual dysfunction, highlighting the importance of prioritizing women’s sexual health. She emphasized the need for a shift in how we view and address women’s sexual health issues, noting that women deserve better care and treatment options. Eckert also clarified that Addyi is not the female equivalent of Viagra, but a unique medication that targets the brain’s desire center to enhance sexual satisfaction.
Looking ahead, Eckert shared updates on The Pinkubator’s upcoming projects, including a revolutionary device designed to improve the epidural process. She encourages aspiring innovators to believe in themselves and seek support from others, emphasizing the power of asking for help and utilizing social media channels for networking and inspiration.
Overall, Cindy Eckert’s dedication to advancing women’s sexual health and her commitment to driving positive change in the healthcare industry continue to make a significant impact on women’s lives.
